Federated Hermes’s XBiotech XBIT Stock Holding History

Federated Hermes’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-448	Closed	-$5K	–	2388
2020 Q1	$5K	Buy	448 +404	+918%	+$6.58K	﹤0.01%	1933
2019 Q4	$1K	Buy	+44	New	+$567	﹤0.01%	2151

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Federated Hermes's XBIT Position: Q2 2020 in Review

Federated Hermes sold out of XBiotech (XBIT) in Q2 2020, closing a stake of 448 shares — an estimated $5K sold.

Federated Hermes first reported a position in XBIT in Q4 2019 and held it in 2 quarters. The position peaked at $5K in Q1 2020. 65 funds tracked by Wall St. Rank hold XBIT as of Q2 2020.

Federated Hermes reported no remaining XBiotech position as of Q2 2020 after selling out during the quarter.
Federated Hermes sold 448 XBiotech shares in Q2 2020, an estimated $5K.
Federated Hermes first reported a position in XBiotech in Q4 2019 and held it in 2 quarters.
Federated Hermes's XBiotech position peaked at $5K in Q1 2020.
65 funds tracked by Wall St. Rank held XBiotech as of Q2 2020.

Based on Federated Hermes's 13F filing for Q2 2020, filed 13 Aug 2020.